Sirolimus, the therapy choice for lymphangioleiomyomatosis (LAM), displayed cytostatic but not cytocidal action, with disease recurrence after withdrawal.
The aim of this study is to identify novel potential biomarkers and therapeutic strategies for LAM patients.
